Doping in sports: A survey of the analytical techniques unmasking the abuse of performance enhancing drugs.

Document Type : Review Article

Authors

Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Alexandria University.

Abstract

The use of illegal performance-enhancing drugs (PEDs) in sports, and other tactics by athletes to gain an unfair competitive advantage is becoming a global concern since it negatively impacts the athlete, participants, and the integrity of sports. Annually, a list of drugs and techniques that are prohibited from being used in sports is published by the World Anti-Doping Agency (WADA). The WADA list consists of different classes, namely, non-approved substances, anabolic androgenic steroids (AAS), peptide hormones, growth factors, related substances and mimetics, beta-2 agonists, hormone and metabolic modulators, diuretics and masking agents, stimulants, narcotics, cannabinoids, glucocorticoids, and beta blockers. Moreover, athletes tend to use other cheating techniques, such as blood doping, urine adulteration, and gene doping, to increase their chances of winning. This review encompasses the various classes of PEDs and methods that are most widely used to enhance the performance of athletes. In addition, herein we discuss some of the most commonly used methods that are implemented in the detection of doping.

Highlights

  • The use of illegal performance-enhancing drugs (PEDs), and other tactics by athletes to gain an unfair competitive advantage is becoming a global concern.
  • A list of drugs and techniques that are prohibited from being used in sports is annually published by the World Anti-Doping Agency (WADA).
  • This work reviews the different classes of PEDs and methods and summarizes the analytical techniques that are implemented in the detection of doping.

Keywords

Main Subjects

References

  1. Werner TC, Hatton CK. Performance-Enhancing Drugs in Sports: How Chemists Catch Users. Journal of Chemical Education. 2011;88(1):34-40.
  2. Bahrke MS, Yesalis CE. The Future of Performance-Enhancing Substances in Sport. The Physician and Sportsmedicine. 2002;30(11):51-3.
  3. International WA-DATPL, wada-ama.org/en/World-Anti-Doping- S, Program/Sports-and-Anti-Doping-Organizations/International-, 2010). SP-LaO.
  4. Azzazy HM, Mansour MM, Christenson RH. Doping in the recombinant era: strategies and counterstrategies. Clinical biochemistry. 2005;38(11):959-65.
  5. Heuberger JA, Cohen AF. Review of WADA prohibited substances: limited evidence for performance-enhancing effects. Sports Medicine. 2019;49(4):525-39.
  6. Martin DM, Baron DA, Gold MS. A review of performance-enhancing drugs in professional sports and their spread to amateur athletics, adolescents, and other at-risk populations. Journal of Addictive Diseases. 2006;25(S1):5-15.
  7. Momaya A, Fawal M, Estes R. Performance-enhancing substances in sports: a review of the literature. Sports Medicine. 2015;45:517-31.
  8. Performance-Enhancing Substances in Sport and Exercise; Bahrke, M. S. Y, C. E., Eds.; Human Kinetics: Champaign, IL, 2002, 33-46. p.
  9. Stojanovic BJ, Göschl L, Forsdahl G, Günter G. Metabolism of steroids and sport drug testing. Bioanalysis. 2020;12(9):561-3.
  10. Balcells G, Pozo OJ, Esquivel A, Kotronoulas A, Joglar J, Segura J, et al. Screening for anabolic steroids in sports: analytical strategy based on the detection of phase I and phase II intact urinary metabolites by liquid chromatography tandem mass spectrometry. Journal of Chromatography A. 2015;1389:65-75.
  11. Forsdahl G, Zanitzer K, Erceg D, Gmeiner G. Quantification of endogenous steroid sulfates and glucuronides in human urine after intramuscular administration of testosterone esters. Steroids. 2020;157:108614.
  12. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid communications in mass spectrometry : RCM. 2004;18(12):1245-049.
  13. Bresson M CV, Kintz P, Villain M, Jenkins T, Joumier JM. Screening for Anabolic Steroids and Their Esters Using Hair Analyzed by GC Tandem Quadrupole MS.
  14. Kintz P, Gheddar L, Raul JS. Simultaneous testing for anabolic steroids in human hair specimens collected from various anatomic locations has several advantages when compared to the standard head hair analysis. Drug Testing and Analysis. 2021.
  15. Dmitrieva E, Temerdashev A, Azaryan A, Gashimova E. Quantification of steroid hormones in human urine by DLLME and UHPLC-HRMS detection. Journal of Chromatography B. 2020;1159:122390.
  16. Catlin DHH, C. K.; Starcevic, S. H. Clin. Chem. 1997, 43,, 1280–1288.
  17. and WA-DAGftR, Management of Elevated T/E Ratios M, version 1, www.
  18. Alzahrani MA, O. Alshuwaier G, S. Aljaloud K, Gibson C, Khalaf A, S. Alhawiti A, et al. Development of a derivatization method for investigating testosterone and dehydroepiandrosterone using tandem mass spectrometry in saliva samples from young professional soccer players pre-and post-training. Scientia Pharmaceutica. 2019;87(2):11.
  19. Du B, Zhang J, Dong Y, Wang J, Lei L, Shi R. Determination of testosterone/epitestosterone concentration ratio in human urine by capillary electrophoresis. Steroids. 2020;161:108691.
  20. Handelsman DJ, Bermon S. Detection of testosterone doping in female athletes. Drug testing and analysis. 2019;11(10):1566-71.
  21. Pelkey CTHRFSP, http://velonews.competitor.com/2009/04/news/ DT, tyler-hamilton-retires-following-second-positive-doping-test_90740, 2010). aO.
  22. Panel TNACoAfSA, AAA USA-DAvFL, Arbitration TNACo, usantidoping.org/files/active/arbitration_ fSp, (accessed rlf--p, 2010). O.
  23. Aguilera RC, T. E.; Starcevic, B.; Hatton, C. K.; Catlin,, D. H. Clin. Chem. 2001, 292–300.
  24. TD2004EAAS WA-DATD, Version 1.0 RaEGfT, Epitestosterone TERaOES, http://www.wada-ama.org/Documents/World_Anti-Doping_, Program/WADP-IS-Laboratories/WADA_TD2004EAAS_EN.pdf, 2010). aO.
  25. Montes de Oca Porto R, Fernández_Hormiga MA, Correa_Vidal MT, Martínez_Brito D. Carbon isotope ratio of endogenous urinary steroids of the Cuban population of athletes studied for doping purposes. Drug Testing and Analysis. 2020;12(10):1501-7.
  26. Aguilera R, Hatton CK, Catlin DH. Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem. 2002;48(4):629-36.
  27. Sobolevskii TG, Prasolov IS, Rodchenkov GM. Carbon isotope mass spectrometry in doping control. Journal of Analytical Chemistry. 2010;65(8):825-32.
  28. Aguilera R, Hatton CK, Catlin DH. Detection of Epitestosterone Doping by Isotope Ratio Mass Spectrometry. Clinical Chemistry. 2002;48(4):629-36.
  29. Schulze J, Pettersson-Bohlin K, Thörngren J-O, Ekström L. Re-evaluation of combined ((ES/EG)/(TS/TG)) ratio as a marker of testosterone intake in men. Drug Testing and Analysis. 2021;13(8):1576-9.
  30. Bowers LD, Technologies to Enhance Oxygen Delivery and, Performance- MtDtUoTTI, Enhancing Technologies in Sports ECa, Scientific Issues; Murray TH, Maschke, K. J.,Wasunna, A. A.,, Eds.; Johns Hopkins University Press: Baltimore M, 2009;, 255-272. p.
  31. Heiland CE, Schickel Y, Lehtihet M, Börjesson A, Ekström L. Supra‐physiological doses of anabolic androgenic steroids impact erythropoietin and blood parameters. Drug Testing and Analysis. 2023;15(6):599-604.
  32. Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Analytical biochemistry. 2002;311(2):119-26.
  33. World Anti-Doping Agency. Technical Document - TD2009EPO, Version 2.0 HotMftI.
  34. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Advances in chronic kidney disease. 2009;16(2):117-30.
  35. Janssens LK, De Wilde L, Van Eenoo P, Stove CP. Untargeted Detection of HIF Stabilizers in Doping Samples: Activity-Based Screening with a Stable In Vitro Bioassay. Anal Chem. 2024;96(1):238-47.
  36. Human WA-DAQaAo, http://www.wada-ama.org/en/Resources/ GHh, Q-and-A/Q-A-Human-Growth-Hormone/ (accessed on October 26, 2010). aO.
  37. Araton HATC, Cheating Endures, Sept 8, 2007., http://select.nytimes.com/2007/09/08/sports/baseball/08araton., 2010). hrsssnaO.
  38. Meinhardt UN, A. E.; Hansen, J. L.; Birzniece, V.; Clifford,, D.; Leung KG, K.; Ho, K. K.Y. Ann. Intern. Med. 2010,, 152.
  39. Epstein DPPICShs, cnn.com/2008/olympics/2008/writers/david_epstein/08/25/doping/, 2010). ihaO.
  40. Bidlingmaier MS, J.; Ernst, A.; Wu, Z.; Keller, A.; Strasburger,, C. J.; Bergmann ACC, 55 (3), 445–453.
  41. McHugh CM, Park RT, SONKsEN PH, Holt RI. Challenges in detecting the abuse of growth hormone in sport. Clinical Chemistry. 2005;51(9):1587-93.
  42. Bidlingmaier M, Strasburger CJ. Growth hormone assays: current methodologies and their limitations. Pituitary. 2007;10(2):115-9.
  43. Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ, et al. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clinical chemistry. 2009;55(3):445-53.
  44. Powrie JK, Bassett EE, Rosen T, Jorgensen JO, Napoli R, Sacca L, et al. Detection of growth hormone abuse in sport. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2007;17(3):220-6.
  45. Fredolini C, Meani F, Reeder KA, Rucker S, Patanarut A, Botterell PJ, et al. Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. Nano research. 2008;1(6):502-18.
  46. Wallace JD, Cuneo RC, Lundberg PA, Rosén T, Jørgensen JOL, Longobardi S, et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. The Journal of Clinical Endocrinology & Metabolism. 2000;85(1):124-33.
  47. Wallace JD, Cuneo RC, Baxter R, Ørskov H, Keay N, Pentecost C, et al. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. The Journal of Clinical Endocrinology & Metabolism. 1999;84(10):3591-601.
  48. Powrie J, Bassett EE, Rosen T, Jørgensen J, Napoli R, Sacca L, et al. Detection of growth hormone abuse in sport. Growth Hormone & IGF Research. 2007;17(3):220-6.
  49. Kay RGB, C.; Velloso, C. P.; Brown, P. R.; Bartlett, C.;, Blazevich AJG, R. J.; Goldspink, G.; Rees, R.; Ball, G. R.;, Cowan DAH, S. D.; Roberts, J.; Teale, P.; Creaser, C. S., Rapid Commun. Mass Spectrom. 2009, 3173–3182.
  50. Bailly-Chouriberry L, Pinel G, Garcia P, Popot M-A, Le Bizec B, Bonnaire Y. Identification of recombinant equine growth hormone in horse plasma by LC-MS/MS: a confirmatory analysis in doping control. Analytical chemistry. 2008;80(21):8340-7.
  51. Thevis M, Walpurgis K, Thomas A, Geyer H. Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation. Current Opinion in Endocrine and Metabolic Research. 2019;9:22-7.
  52. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion‐derived peptide MOTS‐c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry. 2019;33(4):371-80.
  53. Liu Y, Vu V, Sweeney G. Examining the potential of developing and implementing use of adiponectin-targeted therapeutics for metabolic and cardiovascular diseases. Frontiers in endocrinology. 2019;10:842.
  54. Thevis M, Kuuranne T, Geyer H. Annual banned‐substance review–Analytical approaches in human sports drug testing. Drug testing and analysis. 2020;12(1):7-26.
  55. Görgens C, Guddat S, Thomas A, Thevis M. Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (< 2 kDa)–sample preparation, mass spectrometric detection, and data review. Drug testing and analysis. 2018;10(11-12):1755-60.
  56. Sardela V, Martucci M, de Araújo A, Leal E, Oliveira D, Carneiro G, et al. Comprehensive analysis by liquid chromatography Q‐Orbitrap mass spectrometry: Fast screening of peptides and organic molecules. Journal of Mass Spectrometry. 2018;53(6):476-503.
  57. Latres E, Mastaitis J, Fury W, Miloscio L, Trejos J, Pangilinan J, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nature communications. 2017;8(1):1-13.
  58. Bhattacharya I, Pawlak S, Marraffino S, Christensen J, Sherlock SP, Alvey C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF‐06252616), an antimyostatin monoclonal antibody, in healthy subjects. Clinical pharmacology in drug development. 2018;7(5):484-97.
  59. Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM. Locally acting ACE‐083 increases muscle volume in healthy volunteers. Muscle & nerve. 2018;57(6):921-6.
  60. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, et al. A single ascending‐dose study of muscle regulator ACE‐031 in healthy volunteers. Muscle & nerve. 2013;47(3):416-23.
  61. Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, et al. Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals. Diabetes, obesity and metabolism. 2018;20(1):94-102.
  62. Zhu Y, D'Arienzo C, Lou Z, Kozhich A, Madireddi M, Chimalakonda A, et al. LC–MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. Bioanalysis. 2016;8(3):193-204.
  63. Walpurgis K, Thomas A, Dellanna F, Schänzer W, Thevis M. Detection of the human anti‐ActRII antibody Bimagrumab in serum by means of affinity purification, tryptic digestion, and LC‐HRMS. PROTEOMICS–Clinical Applications. 2018;12(3):1700120.
  64. Walpurgis K, Thomas A, Thevis M. Detection of the myostatin‐neutralizing antibody Domagrozumab in serum by means of Western blotting and LC‐HRMS. Drug testing and analysis. 2019;11(11-12):1714-23.
  65. Bougault V, Turmel J, Levesque B, Boulet L-P. The respiratory health of swimmers. Sports Medicine. 2009;39:295-312.
  66. PET JNV-B, Distt-Sonepat HI. Beta 2 agonist: Therapeutic use exemption, misuse in sports and its adverse effect on health.
  67. Allen H, Backhouse SH, Hull JH, Price OJ. Anti-Doping policy, therapeutic use exemption and medication use in athletes with asthma: a narrative review and critical appraisal of current regulations. Sports Medicine. 2019;49(5):659-68.
  68. Gerrard D, Pipe A. Therapeutic use exemptions. Acute topics in anti-doping. 62: Karger Publishers; 2017. p. 55-67.
  69. Kindermann W, Meyer T. Inhaled β(2) agonists and performance in competitive athletes. British Journal of Sports Medicine. 2006;40(Suppl 1):i43-i7.
  70. Jacobson GA, Hostrup M, Narkowicz CK, Nichols DS, Walters EH. Enantioselective disposition of (R, R)‐formoterol,(S, S)‐formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. Drug Testing and Analysis. 2019;11(7):950-6.
  71. Keskin S, Ozer D, Temizer A. Gas chromatography-mass spectrometric analysis of clenbuterol from urine. J Pharm Biomed Anal. 1998;18(4-5):639-44.
  72. Amendola L, Colamonici C, Rossi F, Botre F. Determination of clenbuterol in human urine by GC-MS-MS-MS: confirmation analysis in antidoping control. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;773(1):7-16.
  73. Kolmonen M, Leinonen A, Pelander A, Ojanperä I. A general screening method for doping agents in human urine by solid phase extraction and liquid chromatography/time-of-flight mass spectrometry. Analytica chimica acta. 2007;585(1):94-102.
  74. Koole A, Bosman J, Franke JP, de Zeeuw RA. Multiresidue analysis of beta2-agonist in human and calf urine using multimodal solid-phase extraction and high-performance liquid chromatography with electrochemical detection. Journal of chromatography B, Biomedical sciences and applications. 1999;726(1-2):149-56.
  75. Handelsman DJ. Indirect androgen doping by oestrogen blockade in sports. British Journal of Pharmacology. 2008;154(3):598-605.
  76. https://www.wada-ama.org/sites/default/files/resources/, files/schanzer_development.doc_0.pdf6.
  77. Zarghi A FS, Shafaati A. HPLC determination, detection. olipuf, 66: APSC, 747.
  78. Rodríguez J, Castañeda G, Muñoz L. Rapid determination of letrozole, citalopram and their metabolites by high performance liquid chromatography-fluorescence detection in urine: Method validation and application to real samples. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2013;913-914:12-8.
  79. International WA-DATPL, wada-ama.org/en/World-Anti-Doping- S, Program/Sports-and-Anti-Doping-Organizations/International-, 2018). SP-LaO.
  80. Alquraini H, Auchus RJ. Strategies that athletes use to avoid detection of androgenic-anabolic steroid doping and sanctions. Molecular and Cellular Endocrinology. 2018;464:28-33.
  81. Ventura R, Segura J. Detection of diuretic agents in doping control. Journal of chromatography B, Biomedical applications. 1996;687(1):127-44.
  82. at: WTWLSA, hww-ao-a.
  83. Cadwallader AB dlTX, Tieri A, Botre F. The abuse of, agents dap-edam, in sport doping: pharmacology taaBJ, 16. P.
  84. Esposito S. Doping control analysis of small peptide hormones: Ghent University; 2015.
  85. Carey K. The Detection of Doping in Sport and the Role of Forensic Science. 2018.
  86. Esposito S, Deventer K, T'Sjoen G, Vantilborgh A, Van Eenoo P. Doping control analysis of desmopressin in human urine by LC-ESI-MS/MS after urine delipidation. Biomedical chromatography : BMC. 2013;27(2):240-5.
  87. Anti-Doping. WA-DAABHo, http://www.wada-ama.org/en/About-WADA/History/A-Brief-, 2010). H-o-A-DaO.
  88. Dubuc BTBFTtBHDA, http://thebrain.mcgill.ca/flash/ NA, i/i_03/i_03_m/i_03_m_par/i_03_m_par_amphetamine.html, 2010). aO.
  89. Mitchell GJRttCoBoa, and IIitIUoS, Major OPESbPi, League Baseball. Dec 13 hmmcmn, 2-3. mijaOp.
  90. Schmidt MNoPGDEU, Slightly. The New York Times D, 2009, p B13.
  91. Ahrens BD, Kucherova Y, Butch AW. Detection of stimulants and narcotics by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry for sports doping control. Clinical Applications of Mass Spectrometry in Drug Analysis: Methods and Protocols. 2016:247-63.
  92. Docherty J. Pharmacology of stimulants prohibited by the World Anti‐Doping Agency (WADA). British journal of pharmacology. 2008;154(3):606-22.
  93. Ivanova V, Miller JH, Rabin O, Squirrell A, Westwood S. Harmonization of anti-doping rules in a global context (World Anti-Doping Agency-laboratory accreditation perspective). Bioanalysis. 2012;4(13):1603-11.
  94. Mazzarino M, De la Torre X, Botrè F. A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Analytical and bioanalytical chemistry. 2008;392:681-98.
  95. Murray GJ, Danaceau JP. Simultaneous extraction and screening of diuretics, beta-blockers, selected stimulants and steroids in human urine by HPLC-MS/MS and UPLC-MS/MS. Journal of Chromatography B. 2009;877(30):3857-64.
  96. Thevis M, Schänzer W. Examples of doping control analysis by liquid chromatography-tandem mass spectrometry: Ephedrines, β-receptor blocking agents, diuretics, sympathomimetics, and cross-linked hemoglobins. Journal of chromatographic science. 2005;43(1):22-31.
  97. Polet M, Van Gansbeke W, Van Eenoo P. Development and validation of an open screening method for doping substances in urine by gas chromatography quadrupole time-of-flight mass spectrometry. Analytica chimica acta. 2018;1042:52-9.
  98. Huestis MA, Mazzoni I, Rabin O. Cannabis in Sport: Anti-Doping Perspective. Sports medicine (Auckland, NZ). 2011;41(11):949-66.
  99. Bergamaschi MM, Crippa JAS. Why should cannabis be considered doping in sports? Frontiers in Psychiatry. 2013;4:32.
  100. Znaleziona J, Ginterová P, Petr J, Ondra P, Válka I, Ševčík J, et al. Determination and identification of synthetic cannabinoids and their metabolites in different matrices by modern analytical techniques–a review. Analytica chimica acta. 2015;874:11-25.
  101. Möller I, Wintermeyer A, Bender K, Jübner M, Thomas A, Krug O, et al. Screening for the synthetic cannabinoid JWH‐018 and its major metabolites in human doping controls. Drug testing and analysis. 2011;3(9):609-20.
  102. Musah RA, Domin MA, Walling MA, Shepard JR. Rapid identification of synthetic cannabinoids in herbal samples via direct analysis in real time mass spectrometry. Rapid Communications in Mass Spectrometry. 2012;26(9):1109-14.
  103. Wojek N. Glucocorticoids. Drugs in Sport. 2022:309-25.
  104. Arioli F, Gamberini MC, Pavlovic R, Di Cesare F, Draghi S, Bussei G, et al. Quantification of cortisol and its metabolites in human urine by LC-MSn: applications in clinical diagnosis and anti-doping control. Analytical and Bioanalytical Chemistry. 2022;414(23):6841-53.
  105. Ventura R, Daley-Yates P, Mazzoni I, Collomp K, Saugy M, Buttgereit F, et al. A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. British Journal of Sports Medicine. 2021;55(11):631-42.
  106. Touber M, Van Engelen M, Georgakopoulus C, Van Rhijn J, Nielen M. Multi-detection of corticosteroids in sports doping and veterinary control using high-resolution liquid chromatography/time-of-flight mass spectrometry. Analytica chimica acta. 2007;586(1-2):137-46.
  107. Ahrens BD, Starcevic B, Butch AW. Detection of Prohibited Substances by Liquid Chromatography Tandem Mass Spectrometry for Sports Doping Control. In: Langman LJ, Snozek CLH, editors. LC-MS in Drug Analysis: Methods and Protocols. Totowa, NJ: Humana Press; 2012. p. 115-28.
  108. Mottram DR. Beta blockers. Drugs in Sport: Routledge; 2014. p. 231-8.
  109. Szeleszczuk Ł, Frączkowski D. Propranolol versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder. International journal of molecular sciences. 2022;23(17):10099.
  110. Amendola L, Molaioni F, Botrè F. Detection of beta-blockers in human urine by GC-MS-MS-EI: perspectives for the antidoping control. Journal of pharmaceutical and biomedical analysis. 2000;23(1):211-21.
  111. Deventer K, Van Eenoo P, Delbeke F. Simultaneous determination of beta‐blocking agents and diuretics in doping analysis by liquid chromatography/mass spectrometry with scan‐to‐scan polarity switching. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up‐to‐the‐Minute Research in Mass Spectrometry. 2005;19(2):90-8.
  112. 2024 hww-aoep-ls-atA.
  113. Saugy M, Lundby C, Robinson N. Monitoring of biological markers indicative of doping: the athlete biological passport. British journal of sports medicine. 2014;48(10):827-32.
  114. Mathurin JC, de Ceaurriz J, Audran M, Krafft MP. Detection of perfluorocarbons in blood by headspace solid-phase microextraction combined with gas chromatography/mass spectrometry. Biomedical chromatography : BMC. 2001;15(7):443-51.
  115. Esposito S, Deventer K, T'Sjoen G, Vantilborgh A, Van Eenoo P. Doping control analysis of desmopressin in human urine by LC‐ESI‐MS/MS after urine delipidation. Biomedical Chromatography. 2013;27(2):240-5.
  116. Baoutina A, Alexander IE, Rasko JE, Emslie KR. Potential use of gene transfer in athletic performance enhancement. Molecular therapy. 2007;15(10):1751-66.
  117. Pokrywka A, Kaliszewski P, Majorczyk E, Zembroń-Łacny A. Review genes in sport and doping. Biol Sport. 2014;30(3):155-61.
  118. Azzazy HM, Mansour MM, Christenson RH. Gene doping: of mice and men. Clinical biochemistry. 2009;42(6):435-41.
  119. Perez IC, Le Guiner C, Ni W, Lyles J, Moullier P, Snyder RO. PCR-based detection of gene transfer vectors: application to gene doping surveillance. Analytical and bioanalytical chemistry. 2013;405(30):9641-53.
  120. Baoutina A, Coldham T, Bains G, Emslie K. Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene therapy. 2010;17(8):1022-32.
  121. Fischetto G, Bermon S. From gene engineering to gene modulation and manipulation: can we prevent or detect gene doping in sports? Sports Medicine. 2013;43(10):965-77.
  122. Baron DA, Martin DM, Magd SA. Doping in sports and its spread to at-risk populations: an international review. World Psychiatry. 2007;6(2):118.
  123. Tayade MC, Bhamare SM, Kamble P, Jadhav K. Doping in sports: Current review. Int J Cur Res Rev. 2013;5(7):83-6.
  124. Mazzeo F, Altavilla G, D'elia F, Raiola G. Development of doping in sports: Overview and analysis. Journal of Physical Education and Sport. 2018;18:1669-77.
  125. Morente-Sánchez J, Zabala M. Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports medicine. 2013;43:395-411.

Files

Share

How to cite

Statistics